Modern methods of treatment of locally-advanced and recurrent basal cell carcinoma of the head and neck with using signal pathway inhibitor Hedgehog: сlinical cases
The study objective is to analyze the efficacy of a hedgehog signaling pathway inhibitor in locally advanced and recurrent basal-cell carcinoma (BCC) of the head and neck.Materials and methods. We compared the information from international clinical guidelines and two clinical trials (ERIVANCE and S...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2019-04-01
|
| Series: | Опухоли головы и шеи |
| Subjects: | |
| Online Access: | https://ogsh.abvpress.ru/jour/article/view/385 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839573354044981248 |
|---|---|
| author | A. P. Polyakov E. Iu. Vasileva А. А. Polyakov |
| author_facet | A. P. Polyakov E. Iu. Vasileva А. А. Polyakov |
| author_sort | A. P. Polyakov |
| collection | DOAJ |
| description | The study objective is to analyze the efficacy of a hedgehog signaling pathway inhibitor in locally advanced and recurrent basal-cell carcinoma (BCC) of the head and neck.Materials and methods. We compared the information from international clinical guidelines and two clinical trials (ERIVANCE and STEVIE). We also provide two case reports of a hedgehog signaling pathway inhibitor (vismodegib) use.Results. In the ERIVANCE trial, the objective response rate was 48.5 % in patients with metastatic BCC and 60.3 % in patients with locally advanced BCC. The median progression-free survival was 9.3 and 12.9 months in participants with metastatic and locally advanced BCC respectively. The overall survival reached 33.4 months in patients with metastatic BCC and was not reached in patients with inoperable BCC. According to the results of the STEVIE trial, vismodegib ensured disease control in 93 % of patients with locally advanced BCC and 72 % of patients with metastatic BCC. The median progression-free survival was 24.5 and 13.1 months in participants with locally advanced and metastatic BCC respectively. The majority of vismodegib-realted adverse events in both ERIVANCE BCC and STEVIE trials were grade I/II adverse events. In the two clinical trials, vismodegib at a dose of 150 mg per day during 3 months caused visual reduction of the bone destruction focus, which was confirmed by computed tomography. Patients were recommended to continue therapy with vismodegib.Conclusion. Until recently, there were no treatment standards for late-stage BCC. Currently, hedgehog signaling pathway inhibitors, such as vismodegib, can be considered as a method of choice for patients with inoperable and metastatic BCC, since this therapy demonstrated high efficacy. |
| format | Article |
| id | doaj-art-4ad2a77f14914b788be52a3e01d3d84d |
| institution | Matheson Library |
| issn | 2222-1468 2411-4634 |
| language | Russian |
| publishDate | 2019-04-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли головы и шеи |
| spelling | doaj-art-4ad2a77f14914b788be52a3e01d3d84d2025-08-04T14:05:32ZrusABV-pressОпухоли головы и шеи2222-14682411-46342019-04-0191202710.17650/2222-1468-2019-9-1-20-27331Modern methods of treatment of locally-advanced and recurrent basal cell carcinoma of the head and neck with using signal pathway inhibitor Hedgehog: сlinical casesA. P. Polyakov0E. Iu. Vasileva1А. А. Polyakov2P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center of the Ministry of Health of RussiaP.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center of the Ministry of Health of RussiaN.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaThe study objective is to analyze the efficacy of a hedgehog signaling pathway inhibitor in locally advanced and recurrent basal-cell carcinoma (BCC) of the head and neck.Materials and methods. We compared the information from international clinical guidelines and two clinical trials (ERIVANCE and STEVIE). We also provide two case reports of a hedgehog signaling pathway inhibitor (vismodegib) use.Results. In the ERIVANCE trial, the objective response rate was 48.5 % in patients with metastatic BCC and 60.3 % in patients with locally advanced BCC. The median progression-free survival was 9.3 and 12.9 months in participants with metastatic and locally advanced BCC respectively. The overall survival reached 33.4 months in patients with metastatic BCC and was not reached in patients with inoperable BCC. According to the results of the STEVIE trial, vismodegib ensured disease control in 93 % of patients with locally advanced BCC and 72 % of patients with metastatic BCC. The median progression-free survival was 24.5 and 13.1 months in participants with locally advanced and metastatic BCC respectively. The majority of vismodegib-realted adverse events in both ERIVANCE BCC and STEVIE trials were grade I/II adverse events. In the two clinical trials, vismodegib at a dose of 150 mg per day during 3 months caused visual reduction of the bone destruction focus, which was confirmed by computed tomography. Patients were recommended to continue therapy with vismodegib.Conclusion. Until recently, there were no treatment standards for late-stage BCC. Currently, hedgehog signaling pathway inhibitors, such as vismodegib, can be considered as a method of choice for patients with inoperable and metastatic BCC, since this therapy demonstrated high efficacy.https://ogsh.abvpress.ru/jour/article/view/385locally-advanced/recurrent basal cell carcinomahead and necksignal pathway inhibitor hedgehoghedgehog signaling pathway inhibitorsvismodegib |
| spellingShingle | A. P. Polyakov E. Iu. Vasileva А. А. Polyakov Modern methods of treatment of locally-advanced and recurrent basal cell carcinoma of the head and neck with using signal pathway inhibitor Hedgehog: сlinical cases Опухоли головы и шеи locally-advanced/recurrent basal cell carcinoma head and neck signal pathway inhibitor hedgehog hedgehog signaling pathway inhibitors vismodegib |
| title | Modern methods of treatment of locally-advanced and recurrent basal cell carcinoma of the head and neck with using signal pathway inhibitor Hedgehog: сlinical cases |
| title_full | Modern methods of treatment of locally-advanced and recurrent basal cell carcinoma of the head and neck with using signal pathway inhibitor Hedgehog: сlinical cases |
| title_fullStr | Modern methods of treatment of locally-advanced and recurrent basal cell carcinoma of the head and neck with using signal pathway inhibitor Hedgehog: сlinical cases |
| title_full_unstemmed | Modern methods of treatment of locally-advanced and recurrent basal cell carcinoma of the head and neck with using signal pathway inhibitor Hedgehog: сlinical cases |
| title_short | Modern methods of treatment of locally-advanced and recurrent basal cell carcinoma of the head and neck with using signal pathway inhibitor Hedgehog: сlinical cases |
| title_sort | modern methods of treatment of locally advanced and recurrent basal cell carcinoma of the head and neck with using signal pathway inhibitor hedgehog сlinical cases |
| topic | locally-advanced/recurrent basal cell carcinoma head and neck signal pathway inhibitor hedgehog hedgehog signaling pathway inhibitors vismodegib |
| url | https://ogsh.abvpress.ru/jour/article/view/385 |
| work_keys_str_mv | AT appolyakov modernmethodsoftreatmentoflocallyadvancedandrecurrentbasalcellcarcinomaoftheheadandneckwithusingsignalpathwayinhibitorhedgehogslinicalcases AT eiuvasileva modernmethodsoftreatmentoflocallyadvancedandrecurrentbasalcellcarcinomaoftheheadandneckwithusingsignalpathwayinhibitorhedgehogslinicalcases AT aapolyakov modernmethodsoftreatmentoflocallyadvancedandrecurrentbasalcellcarcinomaoftheheadandneckwithusingsignalpathwayinhibitorhedgehogslinicalcases |